Last $1.59 USD
Change Today -0.0188 / -1.17%
Volume 113.8K
ABIO On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 12:31 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

8001 Arista Place

Suite 430

Broomfield, CO 80021

United States

Phone: 720-940-2200

Fax: 720-208-9261

Arca Biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. The company’s main product candidate is Gencaro (bucindolol hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator that the company intends to evaluate in a new clinical trial for the treatment of atrial fibrillation (AF), in patients with heart failure and left ventricular dysfunction (HFREF). Strategy The company’s mission is to become a biopharmaceutical company developing cardiovascular therapies with an emphasis on genetically-targeted therapies. To achieve this goal, the company is pursuing the following strategies: advance the development of Gencaro. The company plans to focus its efforts on initiating and completing the GENETIC-AF Trial; raise substantial additional funding or complete a strategic transaction; build a cardiovascular pipeline; and leverage its existing assets. Research and Development The company’s research and development expenses totaled $1.1 million, as of December 31, 2012. Significant Events In November 2013, ARCA biopharma, Inc. (ARCA) entered into a Clinical Research Agreement with Duke University’s Duke Clinical Research Institute (DCRI), to serve as the coordinating center and principal investigator for GENETIC-AF (the Study), a planned Phase 2B/3 genetically-targeted, comparative effectiveness clinical trial evaluating Gencaro (bucindolol hydrochloride) as a potential treatment for the prevention of atrial fibrillation in patients with heart failure.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABIO:US $1.59 USD -0.02

ABIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ABIO.
View Industry Companies
 

Industry Analysis

ABIO

Industry Average

Valuation ABIO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARCA BIOPHARMA INC, please visit www.arcabiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.